Skip to content

Organon – Finland logo

Main menu
Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA

  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom

  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

Organon Finland

Contact

Organon Finland Oy
Puolikkotie 8
02230 Espoo
Phone: (+358) 29-170 3520
Email: info.finland@organon.com

Organon R&D Finland Oy

Turku office and lab location: 

Itäinen Pitkäkatu 2B, FI-20520 Turku, Finland 

Lab phone: +358 40 3108019 

Turku office phone: +358 40 310 8041

Oulu lab address is: 

Biologintie 3G, FI-90570, Oulu, Finland 

Lab phone: +358 40 3108030

Adverse Events & Product Quality Complaints & Medical Information

(+358) 29-170 3520
dpoc.finland@organon.com

Partnerships & Transparency

Reporting for 2024
Reporting for 2023
Reporting for 2022
Reporting for 2021

Organon Products

For further medical information related to our products, please contact dpoc.finland@organon.com.

Women's Health

Contraception

  • Nexplanon
  • NuvaRing
  • Mercilon
  • Cerazette

HRT

  • Livial
  • Orgametril

Established Brands & Biosimilars

Dermatology

  • Elocon
  • Diprosalic

Pain

  • Arcoxia

Mens Health

  • Propecia
  • Proscar

CNS

  • Sinemet Depot
  • Sinemet
  • Maxalt
  • Maxalt Rapitab
  • Sycrest
  • Tolvon

 

Cardiovascular

  • Cozaar
  • Cozaar Comp
  • Cozaar Comp Forte
  • Ezetrol
  • Lixiana
  • Renitec
  • Renitec Comp
  • Zocor

Respiratory

  • Aerinaze
  • Aerius
  • Nasonex
  • Singulair
  • Asmanex Twisthaler

Other

  • Fosavance
  • Celeston Chronodose

Biosimilars

  • Ontruzant

Privacy

Laaja tietosuojaseloste haittavaikutusraportoinnissa, tuotevirhe-epäilyissä ja lääkeinformaatiokysymyksissä

Terms of Use

Date of preparation: November 2022. Job code: FI-NON-110038

Organon – Finland logo
  • Cookie Policy
  • Privacy Policy
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept